EagleClaw Capital Managment LLC Boosts Stake in Merck & Co., Inc. (NYSE:MRK)

EagleClaw Capital Managment LLC lifted its stake in Merck & Co., Inc. (NYSE:MRK) by 18.1% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 33,403 shares of the company’s stock after purchasing an additional 5,128 shares during the period. Merck & Co., Inc. accounts for approximately 1.1% of EagleClaw Capital Managment LLC’s holdings, making the stock its 26th largest position. EagleClaw Capital Managment LLC’s holdings in Merck & Co., Inc. were worth $2,810,000 as of its most recent SEC filing.

Several other large investors also recently bought and sold shares of MRK. Nuveen Asset Management LLC increased its stake in shares of Merck & Co., Inc. by 6,517.4% in the 2nd quarter. Nuveen Asset Management LLC now owns 24,307,332 shares of the company’s stock worth $2,038,169,000 after purchasing an additional 23,940,007 shares in the last quarter. BlackRock Inc. increased its stake in shares of Merck & Co., Inc. by 2.3% in the 2nd quarter. BlackRock Inc. now owns 191,863,408 shares of the company’s stock worth $16,087,745,000 after purchasing an additional 4,397,580 shares in the last quarter. Invesco Ltd. increased its stake in shares of Merck & Co., Inc. by 18.4% in the 2nd quarter. Invesco Ltd. now owns 18,309,138 shares of the company’s stock worth $1,535,222,000 after purchasing an additional 2,843,458 shares in the last quarter. Schroder Investment Management Group increased its stake in shares of Merck & Co., Inc. by 67.7% in the 2nd quarter. Schroder Investment Management Group now owns 6,381,329 shares of the company’s stock worth $535,075,000 after purchasing an additional 2,576,060 shares in the last quarter. Finally, UBS Asset Management Americas Inc. boosted its holdings in Merck & Co., Inc. by 20.4% in the 2nd quarter. UBS Asset Management Americas Inc. now owns 11,661,412 shares of the company’s stock worth $977,809,000 after buying an additional 1,972,587 shares during the period. Hedge funds and other institutional investors own 75.02% of the company’s stock.

In other Merck & Co., Inc. news, EVP Richard R. Deluca sold 6,427 shares of the stock in a transaction dated Friday, August 9th. The shares were sold at an average price of $85.09, for a total transaction of $546,873.43. Following the completion of the transaction, the executive vice president now owns 103,223 shares of the company’s stock, valued at approximately $8,783,245.07. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.27% of the stock is owned by corporate insiders.

Several research analysts recently weighed in on the stock. ValuEngine downgraded shares of Merck & Co., Inc. from a “hold” rating to a “sell” rating in a report on Wednesday, October 2nd. Bank of America assumed coverage on shares of Merck & Co., Inc. in a report on Wednesday, October 16th. They issued a “neutral” rating and a $90.00 target price for the company. Mizuho reaffirmed a “buy” rating and issued a $97.00 target price on shares of Merck & Co., Inc. in a report on Friday. Societe Generale set a $105.00 target price on shares of Merck & Co., Inc. and gave the stock a “buy” rating in a report on Tuesday, September 3rd. Finally, JPMorgan Chase & Co. set a $96.00 target price on shares of Merck & Co., Inc. and gave the stock a “buy” rating in a report on Thursday, October 10th. One analyst has rated the stock with a sell rating, three have given a hold rating and fifteen have issued a buy rating to the stock. Merck & Co., Inc. currently has a consensus rating of “Buy” and a consensus price target of $94.00.

Shares of MRK traded down $3.10 during midday trading on Tuesday, hitting $81.42. 1,041,373 shares of the company traded hands, compared to its average volume of 6,929,566. The firm has a 50 day moving average of $84.26 and a 200-day moving average of $82.33. Merck & Co., Inc. has a 52 week low of $66.10 and a 52 week high of $87.35. The stock has a market cap of $216.81 billion, a price-to-earnings ratio of 18.76, a PEG ratio of 1.98 and a beta of 0.53. The company has a debt-to-equity ratio of 0.82, a quick ratio of 0.92 and a current ratio of 1.21.

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings data on Tuesday, July 30th. The company reported $1.30 EPS for the quarter, beating the consensus estimate of $1.16 by $0.14. Merck & Co., Inc. had a net margin of 21.10% and a return on equity of 43.34%. The business had revenue of $11.76 billion during the quarter, compared to the consensus estimate of $10.94 billion. During the same quarter in the prior year, the firm earned $1.06 EPS. The business’s revenue was up 12.4% on a year-over-year basis. Sell-side analysts predict that Merck & Co., Inc. will post 4.91 earnings per share for the current fiscal year.

Merck & Co., Inc. Profile

Merck & Co, Inc provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases.

Featured Article: Benefits of owning preferred stock

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.